Get started
Author

Régis Amblard

Observed names: R. Amblard, Regis Amblard
ORCID: 0000-0002-9050-3116
Observed ORCID: 0000-0002-9050-3116
OpenAlex ID: A5068537378
Detectors assessment for stereotactic radiosurgery with cones
2018 · Nicolas Garnier, Régis Amblard, et al. · Journal of Applied Clinical Medical Physics · 17
PDF
Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al. · Cancer Research Communications · 9
Radiosurgery for classical trigeminal neuralgia: impact of the shot size on clinical outcome
2023 · Cécile Ortholan, Philippe Colin, et al. · The Journal of Headache and Pain · 7
PDF
Quantitative analysis of 99mTc-pertechnetate thyroid uptake with a large-field CZT gamma camera: feasibility and comparison between SPECT/CT and planar acquisitions
2023 · Benjamin Serrano, Régis Amblard, et al. · EJNMMI Physics · 6
PDF
Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis
2024 · Célia Gotorbe, Fabien Segui, et al. · Current Oncology · 4
PDF
Computed tomography sequence integration for enhanced proton therapy in patients with metallic implants
2025 · Daniel Maneval, Luka McNeill, et al. · Physics in Medicine and Biology · 2
In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study
2021 · Christopher Montemagno, Benjamin Serrano, et al. · Biochemistry and Biophysics Reports · 2
PDF
Monte Carlo Validation of Output Factors Measurements in Stereotactic Radiosurgery with Cones
2018 · Nicolas Garnier, Régis Amblard, et al. · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · 1
4930 Mitigating metal-induced artefacts in pencil beam scanning proton therapy using multiple CT modalities
2026 · Claudine HOFVERBERG, Luka McNeill, et al. · Radiotherapy and Oncology
Feasibility of In Vivo Dosimetry in Contact Radiotherapy Using Germanium‐Doped Silica Optical Fibers
2025 · Gevorg Shumilov, Clémence Gentner, et al. · physica status solidi (a)
Figure S6 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
PDF
FIGURE 3 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
FIGURE 6 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
FIGURE 4 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Figure S2 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
FIGURE 1 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Data from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
FIGURE 2 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Figure S5 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
PDF
Data from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
FIGURE 5 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Figure S4 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Table S1 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
PDF
Figure S8 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Figure S3 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Works count: 33
Citation count: 48
H-index: 4
I10-index: 1
Year
Topic
Type